| Ytd | -9.05% | |
| 1y | 2.84% |
| Open | 1.76 | Prev Close | 1.77 | Low | 1.73 | High | 1.82 | Mkt Cap | 481.75M |
| Vol | 1.48M | Avg Vol | 2.10M | EPS | -1.06 | P/E | N/A | Forward P/E | -3.08 |
| Beta | 2.15 | Short Ratio | 2.48 | Inst. Own | 77.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 2.05 | 200-d Avg | 1.68 | 1yr Est | 10.45 |
AUTL News
Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, whic
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, ma
LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get
The next data update from the Phase 1 CARLYSLE trial in patients with SLE has been submitted for pre
LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: A
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million
Autolus Therapeutics (NASDAQ:AUTL) affirms FY2026 sales outlook from $140.000 million-$150.000 milli
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.15) per share which beat the ana
LONDON and GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU
HC Wainwright & Co. analyst Emily Bodnar reiterates Autolus Therapeutics (NASDAQ:AUTL) with a
Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday'
Dow Jones index gained 600 points, CNH Industrial rose 16% after reporting better-than-expected Q2 r
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gr
Company reports preliminary Q2 2026 AUCATZYL net product revenue of approximately $45 million and gr
Autolus Therapeutics maintains a Buy rating, driven by ongoing execution in CAR T-cell therapy, espe
Oncology innovation is reshaping cancer care as AI, immunotherapy and targeted therapies fuel pipeli
LONDON & GAITHERSBURG, Md., July 01, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL
LONDON and GAITHERSBURG, Md., June 25, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU
LONDON and GAITHERSBURG, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AU
After losing some value lately, a hammer chart pattern has been formed for Autolus Therapeutics (AUT
Autolus Therapeutics PLC Sponsored ADR (AUTL) reached a significant support level, and could be a go
LONDON and GAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT
LONDON and GAITHERSBURG, Md., May 21, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUT
TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HI
Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
HC Wainwright & Co. analyst Emily Bodnar maintains Autolus Therapeutics (NASDAQ:AUTL) with a
Autolus Therapeutics NASDAQ: AUTL reported higher first-quarter 2026 product revenue and said its co
Autolus Therapeutics (NASDAQ:AUTL) sees FY2026 sales of $120.000 million-$135.000 million vs $130.06
Autolus Therapeutics (NASDAQ:AUTL) reported quarterly losses of $(0.27) per share which met the anal
AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue of $26.2 million for the first quar
Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, ma
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $
US stock futures up, Nasdaq 100 gains 100 pts. Service Properties Trust (SVC) drops 4% in pre-market
Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowe
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader futu